Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha

Scandinavian Journal of Rheumatology

Volumn 38, Issue 2, 2009, Pages 112-120

  Habib, H M ^a   Taher, T E ^b   Isenberg, D A ^a   Mageed, R A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; ANTIMALARIAL AGENT; FAS LIGAND; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; PROPIDIUM IODIDE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY TITER; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LOW DRUG DOSE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 62249172862     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802409496     Document Type: Article

References (52)

1. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther 2003;10:861-4.
2. Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
3. Pan C, Baumgarth N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999;11:495-506.
4. Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KG. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FccRII. Curr Biol 2000;10:227-30.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-17.
6. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
7. Mandik-Nayak L, Seo S, Sokol C, Potts K, Bui A, Erikson J. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J Exp Med 1999;189:1799-814.
8. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, et al. Bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;58:79-88.
9. Potter PK, Cortes-Hernandez J, Quartier P, Botto M, Walport MJ. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol 2003;170:3223-32.
10. Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004;22:139-45.
11. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
12. Grondal G, Traustadottir KH, Kristjansdottir H, Lundberg I, Klareskog L, Erlendsson K, et al. Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus 2002;11:435-42.
13. Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007;28:114-21.
14. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
15. Munoz LE, van Bavel C, Franz S, Berden J, Hermann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008;17:371-5.
16. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.
17. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-92.
18. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997;100:2622-33.
19. Sytwu HK, Liblau RS, McDevitt HO. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996;5:17-30.
20. Enghard P, Langnickel D, Riemekasten G. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand J Rheumatol 2006;35:209-16.
21. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
22. Lee SH, Park SH, Min JK, Kim SI, Yoo WH, Hong YS, et al. Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 1997;6:603-9.
23. Schotte H, Willeke P, Tidow N, Domschke W, Assmann G, Gaubitz M, et al. Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol 2005;34:114-21.
24. Lu LY, Keng HM, Chu JJ, Lin XT, Hsu CM, Sung PK. TNF receptor I polymorphism is associated with persistent palindromic rheumatism. Scand J Rheumatol 2007;36:278-84.
25. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
26. Charles P, Smeenk R, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
27. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004;6:R535-43.
28. van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007;36:418-23.
29. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002;2:37-45.
30. Tucek-Szabo CL, Andjelic S, Lacy E, Elkon KB, Nikolic-Zugic J. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor. J Immunol 1996;156:192-200.
31. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169:175-94.
32. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
33. Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1343-54.
34. Herndon FJ, Hsu HC, Mountz JD. Increased apoptosis of CD45RO- T cells with aging. Mech Ageing Dev 1997;94:123-34.
35. Hermann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocytes-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1242-50.
36. Gordon C,Matthews N, Schlesinger BC, Akbar AN, Bacon PA, Emery P, et al. Active systemic lupus erythematosus is associated with the recruitment of naive/resting T cells. Br J Rheumatol 1996;35:226-30.
37. Fritsch RD, Shen X, Illei GG, Yarboro CH, Prussin C, Hathcock KS. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum 2006;54:2184-97.
38. Aggarwal S, Gallapudi S, Gupta S. Increased TNF-α-induced apoptosis in lymphocytes from aged humans: changes in TNF-α receptor expression and activation of caspases. J Immunol 1999;162:2154-61.
39. Elzey BD, Griffith TS, Herndon JM, Barreiro R, Tschopp J, Ferguson TA. Regulation of Fas ligand-induced apoptosis by TNF. J Immunol 2001;167:3049-56.
40. Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Sumida T, Nishioka K. Tumour necrosis factor α regulation of the Fas-mediated apoptosis-signaling pathway in synovial cells. Arthritis Rheum 1999;42:519-26.
41. Orlinick JR, Elkon KB, Chao MV. Separate domains of the human Fas ligand dictates self-association and receptor binding. J Biol Chem 1997;272:32221-9.
42. Magalhães MB, da Silva LM, Voltarelli JC, Donadi EA, Louzada-Junior P. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007;36:442-7.
43. Mamoune A, Saraux A, Delaunay JL, Le Goff P, Youinou P, Le Corre R. Autoantibodies to CD45 in systemic lupus erythematosus. J Autoimmun 1998;11:485-8.
44. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
45. Wu A, Hua H, Munson S, McDevitt HO. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002;99:12287-92.
46. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF therapy. J Exp Med 2004;200:277-85.
47. Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol 1996;81:293-302.
48. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
49. Sundararajan R, Cuconati A, Nelson D, White E. Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001;276:45120-7.
50. Beg AA, Baltimore D. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
51. Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, et al. Activation of SAPK/JNK by TNF receptor I through a non-cytotoxic TRAF-2 dependent pathway. Science 1997;275:200-3.
52. Yeh WC, Shahinian A, Speiser D, Kranus J, Billia F, Wakeham A, et al. Early lethality, functional NF-kB activation and increased sensitivity to TNF-induced cell death in TRAF-2 deficient mice. Immunity 1997;7:715-25.